NEW YORK (awp international) – On Wall Street, the US leading index Dow Jones Industrial lost its previous day’s gains on Wednesday. Stock marketers cited mixed US economic data as a burden. For example, the number of newly started residential construction on the real estate market fell surprisingly in October, while the number of building permits rose faster than analysts expected. The latter, however, is very prone to fluctuations, according to the market.
The Dow was down 0.44 percent to 35,983.65 points. The market-wide S&P 500 fell 0.10 percent to 4696.01 points after just barely missed a record high on Tuesday. For the technology-heavy Nasdaq 100, however, it was last up 0.25 percent to 16 351.26 points.
Among the individual stocks, the stocks of Visa stood out. They dropped by around six percent and were the clear loser in the Dow. The online giant Amazon no longer wants to accept payments with the company’s credit cards in the UK. The reason Amazon named “the high fees that Visa charges for processing”. The credit card company reacted with incomprehension and announced that they would continue to work on a solution so that customers could continue to use their cards on Amazon in the future. Amazon’s share certificates were up almost one percent.
In the S&P 500, the shares of Target lost almost five percent. The retailer had raised the outlook for like-for-like sales, but also warned of rising cost pressures in the supply chain.
In contrast, the shares of Lowe’s continued their record hunt and were most recently around two percent in the plus. Contrary to expectations, the retail chain with a focus on DIY articles and household appliances was able to increase like-for-like quarterly sales and raised its sales target. The day before, competitor Home Depot had already convinced with its business figures.
Among the technology stocks, Atea Pharmaceuticals’ shares collapsed and fell to a record low. Most recently there was a minus of a good 23 percent. They suffered from the news that the Swiss industry giant Roche has ended its collaboration with the US company after disappointing study results. The decision comes after Atea did not achieve the set goals in a phase II study about a month ago with the hopeful AT-527, the so-called corona pill.
The Baidu shares listed in New York lost almost six percent and were thus among the weakest values in the Nasdaq 100. Although the Chinese search engine operator had surprisingly good quarterly figures overall, it is confronted with a weaker advertising business./la/he
– .
